Sunday, July 23, 2017 6:30:05 PM
APPLIED DNA SCIENCES – ZACKS ANALYSIS 2016
ZACKS Analysis - Jan 2016
Based on the strong financial performance, recent operational achievements, as well as the company s
strong balance sheet, we maintain our Buy rating for APDN shares and re-set our 12-month price target
to $7.50 per share from previous $10.00 per share due to the current market condition especially the
sentiment to biotech industry.
We are impressed by the continued year over year revenue growth in fiscal 1Q16 even with the
seasonality of the cotton ginning season to the Company's business. We are especially pleased to see that APDN has entered into the lucrative molecular diagnostic market.
This is a huge market with high growth potential in the next decade for the company.
We remain optimistic about APDN s prospect. The company s fundamentals remain strong. The
Company s technology is unique and has competitive advantages over its peers. The Company is well
positioned to boost its top line and bottom line in the coming quarters. According to our long term
financial model, the Company s revenue will grow at a compound annual growth rate (CAGR) of 38% in
the next 4 fiscal years from 2016 to 2020. APDN will become profitable in fiscal 2018 with net income of
$2.9 million or EPS of $0.10 per share. EPS will grow to $0.60 per share in fiscal 2020 based on total
revenue of $45 million.
APDN is a high growth company. In terms of valuation, we apply a P/E of 30x to our estimated EPS of
$0.60 in fiscal 2020, discounted at 25% for 4 years. This way, we get our price target of $7.50 per share.
This values the company at about $180 million in market cap based on 24 million outstanding shares, which is conservative in our view. As long as the Company can execute on its growth strategy correctly,
we believe value should be generated for shareholders
Recent APDN News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/21/2024 01:45:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/21/2024 01:43:01 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/19/2024 04:12:51 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/05/2024 08:27:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:30:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:31:35 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/10/2024 08:55:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/07/2024 08:44:05 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/07/2024 08:01:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:33:44 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/29/2024 04:15:04 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/29/2024 01:44:16 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/24/2024 08:12:25 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/22/2024 08:26:53 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/21/2024 05:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 09:25:33 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/15/2024 01:50:38 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 10:18:33 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:25:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:01:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:05:28 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM